Kyle Landskroner
PhD
Medicine
Clinical Pharmacology
Basel, Switzerland
Kyle Landskroner is a Chief Scientific Officer at Azafaros. An industry expert with 25+ years’ experience, Kyle Landskroner brought a vast knowledge of drug development, including early-stage discovery, pharmacological sciences, pharmacokinetics, toxicology, and pharmacodynamics to Azafaros. Before joining the company in 2020, Dr Landskroner worked for Novartis International AG, where he held the position of Director of Global Integration and Separation Office. Before this, he served as Director of Portfolio Management, Global Drug Development, Portfolio Strategy, and Innovation at Novartis, where he led strategic reviews, clinical projects within therapeutic areas, and value-driven decision analyses for the development portfolio.
From 2008 until 2012, he held the position of Senior Laboratory Head at the Department of Preclinical Drug Metabolism and Pharmacokinetics at Actelion Pharmaceuticals in the areas of lysosomal storage diseases and pulmonary hypertension. Prior to Actelion, Kyle worked for Bayer Corporation in Berkeley, California, and Raleigh, North Carolina in various scientific positions in toxicology and pharmacology. This included the role of Staff Scientist within Preclinical Development, with a focus on protein therapeutics for hemophilia and other thrombotic diseases. Kyle received his Ph.D. from the College of Veterinary Medicine at North Carolina State University in the USA.